HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price target from $26 to $17.
HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price target from $26 to $17.